66th ASH Annual Meeting: ASH Poster Walk on Blood Immunology & Cellular Therapy: Advancing Innovations and Translational Insights Hosted by Blood Immunology & Cellular Therapy (For In-person Participants)

ASH Poster Walks

Research, Clinical trials, Lymphoid Leukemias, ALL, Hodgkin lymphoma, Acute Myeloid Malignancies, AML, MDS, CLL, Lymphomas, Non-Hodgkin lymphoma, APL, MPN, Clinical Research, Health outcomes research, LGL, B Cell lymphoma, Plasma Cell Disorders, CML, T Cell lymphoma, Chronic Myeloid Malignancies, CMML, Diseases, Indolent lymphoma, Aggressive lymphoma, Immunology, Lymphoid Malignancies, Myeloid Malignancies, Biological Processes

Halls G-H - Blood Journals Studio (San Diego Convention Center)

Cellular therapies have revolutionized the treatment landscape of blood disorders, offering novel approaches in immunotherapy and transplantation. This poster walk will provide a crucial platform to discuss cutting-edge research and developments in this area. Focused on themes such as experimental transplantation, adoptive immunotherapy, and clinical outcomes in both allogeneic and autologous settings, this walk will showcase the most exciting findings in the posters featured in this year’s Annual Meeting.

Participants can expect to delve into topics ranging from basic biology and pre-clinical models to acute transplant toxicities and immune reconstitution. By featuring presentations on conditioning regimens, graft-versus-host disease (GVHD), and disease recurrence, the event aims to foster deep insights and collaboration among researchers, clinicians, and industry professionals. Attendees will gain valuable perspectives on current challenges and future directions in cellular therapy and immunodiagnostics, enhancing their ability to translate research discoveries into clinical practice.

Join us in the Blood Studio located in the main Poster Hall for this in-person poster walk hosted by ASH’s Blood Immunology & Cellular Therapy journal.

2080

Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Disease

Milos D Miljkovic, MD, MSc¹, Adam S. Asch, MD²^*, Gregory Orloff, MD³^*, Ralph Boccia, MD⁴^*, Jesús G Berdeja, MD⁵, Fevzi Altuntas, MD⁶^*, Stefan O. Ciurea, MD⁷, James F Howard Jr., MD⁸^*, Tuan Vu, MD⁹^*, Bennett Myers, MD¹⁰^*, Nizar Chahin, MD¹¹^*, Tahseen Mozaffar, MD¹²^*, Christopher M Jewell, PhD¹^* and Metin Kurtoglu, MD, PhD¹^*

¹Cartesian Therapeutics, Gaithersburg, MD
²Oklahoma University/Stephenson Cancer Center, Oklahoma City, OK
³Virginia Cancer Specialists, Fairfax, VA
⁴Center for Cancer and Blood Disorders, Johns Hopkins Medicine, Bethesda, MD
⁵Sarah Cannon Center For Blood Cancers, Nashville, TN
⁶Ankara Oncology Training and Research Hospital, Yenimahalle/Ankara, Ankara, Turkey
⁷Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, Orange, CA
⁸Department of Neurology, University of North Carolina Chapel Hill, Chapel Hill, NC
⁹Department of Neurology, University of South Florida, Tampa, FL
¹⁰DENT Neurologic Institute, Buffalo, NY
¹¹Department of Neurology, Oregon Health and Sciences University, Portland, OR
¹²Department of Neurology, University of California Irvine, Irvine, CA

2131

A Phase II Study of Low Dose Melphalan with Thiotepa and Fludarabine As Preparative Regimen for Alternative Donor Transplantation

Nikki Agarwal, MD¹^*, Pingfu Fu, PhD²^*, Michael Daunov, DO¹, Brenda W Cooper, MD^1,2, Ben K. Tomlinson, MD^1,2, Rebecca B. Klisovic, MD¹, Marcos de Lima³^*, Folashade Otegbeye, MBBChir, MPH⁴, Changchun Deng, MD, PhD^1,2, Yeritza Hernandez-Collazo¹^*, Jignesh Dalal, MD¹^*, James Martin, MD^1,2, Seunghee Margevicius²^*, James J. Ignatz-Hoover, MD, PhD¹^*, Ok-Kyong Chaekal, MD^1,2^*, Molly Megan Gallogly, MD, PhD^1,2, Koen van Besien, MD, PhD^1,2 and Leland Metheny, MD^1,2

¹Department of Hematology and Stem Cell Transplant, University Hospitals Seidman Cancer Center, Cleveland, OH
²Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
³Ohio State University, Columbus, OH
⁴Fred Hutchinson Cancer Center, SEATTLE, OH

3453

A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)

Maria Lia Palomba, MD¹, Paolo F. Caimi, MD², Matthew Mei, MD³, Francisco Hernandez-Ilizaliturri, MD⁴, Geoffrey Shouse, PhD, DO³, Allison M. Winter, MD², Greg Yedinak⁵^*, David Mou⁵^*, Nestor Huang⁵^*, Anna Moua, BS⁵^*, Martin Oft, MD⁵^*, Paul-Joseph Aspuria, PhD⁵^*, Anita Mehta-Damani, PhD⁵^*, Naiyer Rizvi, MD⁵^*, Sherry Unabia⁵^*, Peg Taylor, BS⁵^*, Jeffrey McLeroy⁵^* and Matthew J Cortese, MD, MPH⁴

¹Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
²Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
³City of Hope National Medical Center, Duarte, CA
⁴Department of Medicine (Lymphoma Section), Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁵Synthekine Inc, Menlo Park, CA

2078

Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies

Sumithira Vasu, MD, MBBS¹, Evandro Bezerra, MD^2,3, Nathan Denlinger, DO, MS⁴, Nicole Szuminski¹^*, Dina Schneider, PhD⁵, Pradyot Dash, PhD⁶, Louisa Wirthlin⁷^*, Narendranath Epperla, MD, MS⁸, Yazeed Sawalha, MD⁴, Jennifer A. Woyach, MD⁹, Kerry A. Rogers, MD⁴, Seema A Bhat, MD⁴, Gregory K Behbehani, MD, PhD¹⁰, Karilyn T. Larkin, MD¹⁰, Adam S Kittai, MD¹¹, Wing Chan, PhD¹², Ashley Angell Krull¹³^*, Shamama Nishat, PhD¹^*, Lynn O'Donnell, PhD¹^*, Lapo Alinari, MD, Ph.D¹² and Marcos de Lima, MD¹⁴

¹The Ohio State University, Columbus, OH
²Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH
³Division of Hematology, The Ohio State University, Upper Arlington, MN
⁴Division of Hematology, The Ohio State University, Columbus, OH
⁵Lentigen, Gaithersburg, MD
⁶Lentigen, a Miltenyi Biotec Company, Gaithersburg, MD
⁷Miltenyi Biotec, Gaithersburg, MD
⁸Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH
⁹Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus, OH
¹⁰Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH
¹¹Icahn School of Medicine at Mount Sinai, New York, NY
¹²James Comprehensive Cancer Center, The Ohio State University, Columbus, OH
¹³The Ohio State University Wexner Medical Center, Columbus, OH
¹⁴Department of Internal Medicine, Division of Hematology, The Ohio State University - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH

See more of: ASH Poster Walks

<< Previous Poster Walk Application | Next Poster Walk Application >>